Related Experiment Videos
Randomized controlled trial of transfer factor in Stage II malignant melanoma
Cancer
|January 15, 1983
Summary
This study investigated transfer factor (TF) as an adjuvant therapy for malignant melanoma. Results showed no statistically significant benefit of TF in improving disease-free intervals or survival rates for Stage II patients.
Area of Science:
- Oncology
- Immunology
Background:
- Malignant melanoma is a significant health concern.
- Adjuvant therapies are crucial for improving outcomes after surgical resection of melanoma.
Purpose of the Study:
- To evaluate the efficacy of transfer factor (TF) as an adjuvant therapy for Stage II malignant melanoma.
- To determine if TF improves disease-free interval and survival rates post-surgery.
Main Methods:
- Thirty-six patients with Stage II malignant melanoma were randomized.
- Patients were assigned to either surgery plus transfer factor (TF) or surgery alone.
- Disease-free intervals and survival times were compared between the two groups.
Main Results:
- Median disease-free intervals were 12.0 months for TF and 10.0 months for controls.
- Median survival was 40.8 months for TF and 27.0 months for controls.
- The observed differences in disease-free intervals and survival were not statistically significant.
Conclusions:
- Transfer factor (TF) did not demonstrate a statistically significant adjuvant effect in Stage II malignant melanoma patients.
- Further research may be needed to explore TF's role in melanoma treatment.